Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fourth Act For AbbVie's Risankizumab Whets Appetite

Executive Summary

AbbVie has released more positive top-line data for its anti-IL23 product risankizumab, building a strong case for its use in psoriasis – but there is still more to come from the study amid uncertainty over how the product will deal with competitive and pricing pressure.

Advertisement

Related Content

AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval
AbbVie's Skyrizi Poised To Enter Packed Psoriasis Market
Almirall To Put More Skin In The Game With Derma Buys
Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab
HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last
AbbVie's Spin-Out Culture Helped Set Post-Humira Strategy, Execs Say
AbbVie's Spin-Out Culture Helped Set Post-Humira Strategy, Execs Say
AbbVie's Spin-Out Culture Helped Set Post-Humira Strategy, Execs Say

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100002

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel